Using Magnetocardiography to Identify Tachyarrhythmia Origins

Magnetocardiography for Precise Identification of the Site of Origin of Tachyarrhythmia

This study is testing if a special heart imaging technique can help find where fast heart rhythms start in patients with tachyarrhythmia to improve their treatment.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 1000 (estimated)
• Ages: 18 Years to 79 Years
• Sex: All
• Sponsor: Qilu Hospital of Shandong University (other)
• Locations: 1 site (Jinan, Shandong)
• Trial ID: NCT06327425 on ClinicalTrials.gov

What this trial studies

This research aims to accurately locate the origin of tachyarrhythmias using Magnetocardiography (MCG). By identifying the site of origin, the study seeks to enhance early diagnosis and inform treatment plans, particularly for radiofrequency ablation procedures. Participants will undergo MCG and cardiac electrophysiologic examinations to assess their conditions. The study focuses on patients diagnosed with various forms of tachyarrhythmia, ensuring they are stable and capable of participating in the evaluations.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-79 with stable paroxysmal supraventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, or premature ventricular contractions.

Not a fit: Patients with known structural heart diseases or significant cardiovascular history may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more precise diagnoses and improved treatment strategies for patients with tachyarrhythmias.

How similar studies have performed: While this approach using MCG is innovative, similar studies have shown promise in improving diagnostic accuracy for cardiac conditions.

Eligibility criteria

Inclusion Criteria:

* Age 18-79 years old;
* Those whose conditions are comparatively stable and who have been diagnosed by an attending physician （or physicians with higher qualifications） with paroxysmal supraventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, or premature ventricular contractions, and who are capable of performing MCG and cardiac electrophysiologic examinations after evaluation.
* Signed informed consent.

Exclusion Criteria:

* Those with known structural heart disease such as cardiomyopathy and valvular disease;
* Those with history of other cardiovascular diseases such as pulmonary embolism and aortic dissection;
* Those with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications;
* Those with obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply;
* Those with Obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2);
* Those with malignant tumors;
* Professional athletes, pregnant or breastfeeding women, alcoholics;
* Those with acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.;
* Those with infectious diseases or communicable diseases;
* Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.;
* Unable to or fail to cooperate with the corresponding research requirements.

Where this trial is running

Jinan, Shandong

• China, Shandong Qilu Hospital of Shandong University — Jinan, Shandong, China (RECRUITING)

Study contacts

• Principal investigator: Yuguo Chen, Professor — Qliu Hospital of Shandong University
• Study coordinator: Jiaojiao Pang, Doctor

Conditions: Tachyarrhythmia, Atrial Flutter, Paroxysmal Supraventricular Tachycardia, Atrial Tachycardia, Atrial Fibrillation, Premature Ventricular Contraction